Obese people with type 2 diabetes may also be a good candidate group for studies to confirm the anti-obesity effect of the combined treatment of butyrate and an SGLT-2 inhibitor. The gene discussed is SLC5A2; the disease is obesity due to melanocortin 4 receptor deficiency.